Kazia Therapeutics Limited
KZIA · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.04 | -0.02 | 0.33 |
| FCF Yield | -122.65% | -47.24% | -28.24% | -5.89% |
| EV / EBITDA | -0.25 | -1.29 | -3.19 | -24.86 |
| Quality | ||||
| ROIC | 787.50% | -109.52% | -78.44% | -13.52% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.64 | 0.36 | 0.74 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 322.98% | 513.40% | -96.68% | -78.37% |
| Free Cash Flow Growth | 36.78% | 33.41% | -149.83% | -3.41% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | 0.15 | 0.23 | 5.40 |
| Interest Coverage | 0.00 | 0.00 | -12,129.42 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 21.03 | 401.17 | 1,861.50 | 1.83 |